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Abstract
Background: Small fiber neuropathy is the most common cause of neuropathic pain in peripheral neuropathies,
with a minimum prevalence of 53/100,000. Patients experience excruciating pain, and currently available anti-
neuropathic and other pain drugs do not relieve the pain substantially. Several open-label studies have suggested
an immunological basis in small fiber neuropathy and have reported efficacy of treatment with intravenous
immunoglobulin. Therefore, immunological mechanisms conceivably may play a role in small fiber neuropathy. To
date, no randomized controlled study with intravenous immunoglobulin in patients with small fiber neuropathy has
been performed.
Methods/design: This study is a randomized, double-blind, placebo-controlled, clinical trial in patients with idiopathic
small fiber neuropathy. The primary objective is to investigate the efficacy of intravenous immunoglobulin versus
placebo on pain alleviation. A 1-point change in the PI-NRS compared to baseline is considered the minimum clinically
important difference. In the IVIg-treated group, we assume a response rate of approximately 60 % based on the criteria
composed by the IMMPACT group for measurement of pain. Based on this, a sample size of 60 patients is needed.
Eligible patients fulfilling the inclusion/exclusion criteria will be randomized to receive either intravenous
immunoglobulin or placebo (0.9 % saline). The treatment regimen will start with a loading dose of 2 g/kg body
weight over 2–4 consecutive days, followed by a maintenance dose of 1 g/kg body weight over 1–2 consecutive
days given three times at a 3-week interval. The primary endpoint is the comparison of the percentage of
responder subjects between the two treatment groups from the first randomization during the 12 weeks of
treatment. A responder is defined as ≥ 1-point Pain Intensity Numerical Rating Scale improvement on the mean
weekly peak pain relative to baseline. The secondary outcomes are pain intensity, pain qualities, other small fiber
neuropathy-related complaints, daily and social functioning, as well as quality of life. In addition, safety
assessments will be performed for adverse events, vital signs, and laboratory values outside the normal range.
Responders during the 12-week treatment period will be followed during a 3-month extension phase.
Discussion: This is the first randomized, double-blind, placebo-controlled clinical trial with intravenous
immunoglobulin in patients with idiopathic small fiber neuropathy. Positive findings will result in a new
treatment option for small fiber neuropathy and support an immunological role in this condition.
Trial registration: ClinicalTrials.gov, NCT02637700. Registered on 16 December 2015.
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Background
Small fiber neuropathy (SFN) is a disorder of the thinly
myelinated Aδ-fibers and the unmyelinated C-fibers,
with a minimum prevalence of 53/100,000 [1]. Patients
suffer from neuropathic pain, usually according to a
length-dependent pattern [2]. In addition, they report
autonomic symptoms such as palpitations, gastrointes-
tinal disturbances, and orthostatic dizziness [3, 4]. SFN
interferes with daily functioning and may lead to a dec-
rement in quality of life expectations [5]. The diagnosis
is based on SFN-related symptoms, without signs of
large fiber involvement, in combination with an abnor-
mal intraepidermal nerve fiber density (IENFD) in skin
biopsy and/or abnormal temperature threshold levels in
quantitative sensory testing [3, 4]. Despite intensive
search for underlying causes such as diabetes mellitus,
impaired glucose tolerance, Fabry’s disease, hereditary
disorders, celiac disease, sarcoidosis, HIV, and other sys-
temic illnesses that may be potentially treatable [3, 4],
the proportion of patients with idiopathic SFN (I-SFN)
remains substantial, ranging in different series from
24 % up to 93 % [1, 6–8]. Conceivably, immunological
mechanisms may play a role in patients with I-SFN, as
several immune-mediated diseases such as sarcoidosis,
Sjogren’s disease, and systemic lupus erythematosus are
associated with SFN [8–11]. Autoantibodies have also
been reported in patients with SFN [12–14]. Moreover, in-
flammatory changes in nerves have been found [15, 16].
Elevated proinflammatory cytokines have been suggested
to be involved in the pathophysiology of pain in SFN [17].
In other immune-mediated neuropathies such as chronic
inflammatory demyelinating polyneuropathy, treatment
with intravenous immunoglobulin (IVIg) has proven to be
efficacious [18, 19]. Moreover, some immunomodula-
tion therapies have shown efficacy in some open-label
case studies in patients with SFN with chronic pain
[20–24]. Similar findings have been reported in ery-
thromelalgia, a condition that is associated with SFN
[25, 26]. Pain reduction with IVIg treatment has been
summarized recently [23].
IVIg is a blood product with high doses of pooled IgG
molecules, which are derived from thousands of donors.
IgG antibodies are the primary mediators of protective
humoral immunity against pathogens but can also be
pathogenic [27]. IVIg may be used either to boost the pa-
tients' immunological capabilities or, conversely, to blunt
an immune response directed toward the patients’ own tis-
sues [28]. This dual IVIg-mediated effect on the immune
system makes IVIg suitable for the treatment of several dif-
ferent diseases. When administered in high concentrations,
IVIg has anti-inflammatory properties. How this anti-
inflammatory effect is mediated has not been fully eluci-
dated yet. Several mechanisms have been proposed,
including toxin inactivation, stimulation of the leukocyte
and serum bactericidal action, modulation of cytokine ef-
fect, and the modulation of the complement system [28].
In SFN, current neuropathic pain treatment options
are generally insufficient to relieve the pain substantially
[29, 30]. Therefore, a better treatment is warranted. IVIg
appears to be a potential therapeutic option for pain al-
leviation in SFN. The aim of the current pilot study is to
investigate the efficacy and safety of IVIg in patients




The primary objective of the study is to evaluate the effi-
cacy of IVIg treatment for pain alleviation compared to
placebo in patients with skin-biopsy-proven I-SFN.
Secondary objectives are to assess the effect of IVIg on
pain intensity, pain qualities, and other small fiber
neuropathy-related complaints and daily and social func-
tioning, as well as quality of life. In addition, safety fea-
tures of IVIg therapy in SFN will be evaluated.
Study design
The study has a randomized, double-blind, parallel
group, placebo-controlled prospective design, which is
shown in Fig. 1. This design has been partly applied
and published previously [18, 31]. This design has
been partly applied and published previously in the
ICE-trial, in which the effect of IVIg for the treat-
ment of chronic inflammatory demyelinating polyradi-
culopathy has been studied [18]. In that study, a
screening period up to 10 days was chosen; thereafter,
patients were divided into one of the two parallel
groups: IVIg or placebo. Patients received a baseline-
loading dose of 2 g/kg over 2–4 days, followed by a
maintenance infusion of 1 g/kg over 1–2 days every
3 weeks. For the current trial, this part of the study
design has been adopted.
In brief, after a screening period of ≤ 10 days, eligible
subjects are randomized to receive either IVIg at an
uploading dose of 2 g/kg body weight (bw), ideally over
2–4 (consecutive) days, or a matching placebo. There-
after, a study drug infusion is administered every 3 weeks
at a dose of 1 g/kg bw, given over 1–2 (consecutive)
days for a total of three additional infusions following
baseline. The subjects’ pain is measured using Pain In-
tensity Numerical Rating Scale (PI-NRS) at baseline and
at each study visit scheduled every 3 weeks for 12 weeks.
Pain is also assessed twice a day (daytime and nocturnal
pain, through PI-NRS) on 2 days each week (Monday
and Friday). A responder is defined as a ≥ 1-point im-
provement on the mean weakly peak pain using the PI-
NRS relative to baseline. Patients who show an im-
provement and complete the 12 weeks of study
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treatment will be followed during a 3-month-extension
phase to determine the long-term effect of the received
therapy on pain alleviation.
The study is placebo-controlled because in previous
analgesic trials a placebo effect of 7-37 % has been
shown [32]. To make sure IVIg has a factual effect
on pain reduction, a placebo-controlled design is ne-
cessary to exclude the placebo effect of this treatment
on the patients. In addition, patients are allowed to
use pain medication that not has been changed in the
30 days prior to randomization. As a result, in case
the patient receives a placebo, the treatment does not
differ from the situation before participating in the
study.
Setting and duration
The study is conducted at the department of Neur-
ology of the Maastricht University Medical Center
(Maastricht UMC+), Maastricht, the Netherlands. For
logistical reasons, all subjects are residents of the
Netherlands. The duration of the study is 6 months
per subject. Examination will be performed by neuro-
muscular experts and/or highly trained fellows in
neurology. We are aiming to conduct the study in a
2-year period.
Participants
A total of 60 patients, 30 per treatment arm, will be
included in the study. These are patients with newly or
previously diagnosed skin-biopsy-proven idiopathic (pre-
dominantly) SFN. Subjects are recruited at the Maas-
tricht UMC+, the Netherlands. Informed consent will
be obtained from all participants before the study start.
Inclusion criteria
Subjects must meet all of the following inclusion criteria
to be eligible for enrollment into the study:
1. Participant must be 18 years of age or older.
2. Skin-biopsy proven idiopathic SFN or idiopathic
painful neuropathy with a predominant SFN pattern
must be present.
3. Pain intensity rated ≥ 5 on the PI-NRS (maximum
pain) or on the neuropathic pain scale (NPS) [33, 34],
question number 1, must have existed for at least
12 weeks before the study, as declared by each patient
to the best of their knowledge; if available, the
medical records of each patient will be consulted
on the reported pain intensity.
4. Each subject will receive an information leaflet and
an informed consent form. Subjects must give










= 2 g/kg IGIV or Placebo
Follow-up period: 
3 months
Week 0 Week 3 Week 6 Week 9
= 1 g/kg IGIV or Placebo
= treatment visit= visit
Week 1 Week 12
Month 4 Month 5 Month 6
= telephone call
Fig. 1 Schematic diagram representing overall study design and study visitsLegend: IVIg = intravenous immunoglobulin, red triangles represent
the treatment visits. The first treatment visit is spread out over 2-4 consecutive days, treatment visit 2-4 will consist of 1-2 consecutive days
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5. Eligible patients must be willing to complete all
study-related activities and examination required by
the protocol.
Exclusion criteria
Subjects presenting with any of the following will not be
included in the study:
1. Predominant clinical picture of large nerve fiber
involvement (i.e., weakness, loss of vibration sense,
and hyporeflexia or areflexia)
2. Treatment with IVIg or any other
immunomodulatory/immunosuppressive agents
(e.g., steroids) within the last 12 weeks prior to the
date of informed consent
3. An underlying cause of SFN (diabetes, SCN9A/
SCN10A/SCN11A mutations, hypothyroidism, renal
failure, vitamin B12 deficiency, monoclonal
gammopathy, alcohol abuse (more than 5 IU/day),
malignancies, or drugs that cause neuropathy (e.g.,
chemotherapy, amiodarone, and propafenone))
4. History of anaphylaxis or severe systemic response
to immunoglobulin or with a blood product
5. Cardiac insufficiency (NYHA III/IV),
cardiomyopathy, significant cardiac dysrhythmia
requiring treatment, unstable or advanced ischemic
heart disease, history of congestive heart failure, or
severe hypertension (diastolic blood pressure >
120 mmHg or systolic > 170 mmHg)
6. Known hyperviscosity, history of renal insufficiency
or high serum creatinine levels (MDRD < 30),
selective IgA deficiency, or hypercoagulable state.
7. Conditions whose symptoms and effects could alter
protein catabolism and/or IgG utilization (e.g.,
protein-losing enteropathies, or nephrotic syndrome).
8. Females who are pregnant, breast-feeding, or, if of
childbearing potential, unwilling to practice adequate
contraception throughout the study
9. Mentally challenged adult subjects unable to give
independent informed consent
10.Patients using pain medication that has changed in
the 30 days prior to randomization (unchanged pain
medication is allowed, provided dosages stay equal
during the study)
Study medication
Gamunex© 10 %, 100 mg/ml, solution for infusion is a
human normal immunoglobulin that is currently avail-
able commercially in a number of countries for the
treatment of primary immunodeficiency, idiopathic
thrombocytopenic purpura, and chronic inflammatory
demyelinating polyneuropathy, as well as other indica-
tions in some countries. Placebo is supplied as 0.9 %
saline.
The dose of IVIg chosen for this study has been con-
sidered to be potentially the most effective in other
immune-mediated polyneuropathies, specifically 2.0 g/kg
of IVIg as loading dose followed by 1 g/kg bw for main-
tenance at intervals of 3 weeks [18].
The maximum dose is 80 g IVIg per infusion day, even
for subjects whose body weight exceeds 80 kg. The max-
imum dose is 160 g IVIg for a 2 g/kg bw application and
80 g for 1 g/kg/bw application.
The calculated dose is administered over a 2- to 4-day
period at baseline, dividing the total dose equally among
the amount of infusion days. The infusion will be pre-
pared on the day of infusion and administered on that
same day. The three additional infusions, given at subse-
quent study visits, are each administered as a single infu-
sion on 1 day but may be given over 2 consecutive days
for reasons of tolerability.
On the first 2 days of the treatment (day 1 and day 2),
the initial infusion rate will be 0.05 mL/kg/hour for the
first 20 min. If no evidence exists of a hypersensitivity
reaction, the infusion rate will be increased to 1.0 mL/
kg/hour for the next 20 min. After that, the infusion rate
will be increased to 3.0 mL/kg/hour. If this is well toler-
ated, the infusion rate will start at 1 mL/kg/hour for
additional treatments and will be increased to 3 mL/kg/
hour and 5 mL/kg/hour over 20 minutes up to a max-
imum allowable rate of 7 mL/kg/hour. This infusion
scheme is according to the protocol of the hospital. Each
infusion will take approximately 3–4 h. Vital signs will
be documented during the infusion. The subject will be
monitored during the infusion for any adverse events.
Compliance
The volume of the study drug administered will be doc-
umented in the medical record and the electronic case
report file (eCRF). When less than 100 % of the calcu-
lated study drug volume is given, the reasons for devi-
ation will be recorded in the medical record and eCRF.
Randomization and blinding
All eligible subjects participating in the study will receive
a subject number consecutively beginning with the ab-
breviation of the study (IVIG) followed by 01, 02, or 03,
etc. A computer will randomize the subjects to one of
the two treatment groups. An automatic message with
this allocation will be send to the unblinded pharmacist
and will remain confidential.
The study will be subject and investigator blinded dur-
ing the treatment periods, from visit 2 until the end of
the study. Blinding codes will only be broken in emer-
gency situations for reasons of subject safety.
Blinding of different study groups will be guaranteed
by ensuring all subjects receiving the same total volume
per kilogram of body weight of trial medication, with no
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visible difference in the external aspect between IVIg
and placebo, by using nontransparent infusion lines and
bags. An unblinded pharmacist or designee will prepare
study medication. This individual, responsible for dis-




The primary outcome measure will be based on pain as-
sessment, as pain is considered the most important fea-
ture of SFN [2–4, 35, 36]. Pain intensity will be
evaluated using the 11-point Pain Intensity Numeric
Rating Scale (PI-NRS; 0, no pain, to 10, worst imaginable
pain) [33, 37]. In particular, a difference in the mean
weakly peak pain intensity will be considered as the pri-
mary outcome parameter. A responder is defined as ≥ 1-
point improvement on the PI-NRS during the 12-week
treatment relative to baseline. The rationale for choosing
the primary outcome measure was based on recommen-
dations regarding the clinical importance of treatment
outcomes in chronic pain clinical trials as postulated by
the IMMPACT (Initiative on Methods, Measurements and
Pain Assessment in Clinical Trials) study group [38, 39].
Secondary outcomes
Secondary outcome measures include changes in the daily
pain intensity, nocturnal pain intensity, and the average of
these two obtained from the PI-NRS, change in patients’
global impression of change (PGIC) [38, 39], the Rash-
transformed 13-item SFN Symptoms Inventory Question-
naire (RT-SFN-SIQ) [40], the amount of pain medication,
the use of nonmedical rescue activities, the amount of
pain relief (using a 5-point Likert-scale), the NPS [34], the
Daily Sleep Interference Scale (DSIS), the Short Form 36
Health Survey (SF-36) [41, 42], and the Rasch-built Over-
all Disability Outcome Scale (SFN-RODS) [40].
Safety evaluation features will include the following
additional tests: adverse events, laboratory test (e.g.,
hematology and clinical chemistry, as shown in Table 2),
and vital signs.
Data management
An eCRF is used for each patient to collect all data. To
host the eCRF, MACRO electronic data capture is used,
powered by InferMed Ltd, London. It has been de-
signed to support compliance with the requirements of
relevant regulatory bodies including ICH Good Clinical
Practice (www.infermed.com). Assessments start at the
screening visit, are subsequently performed according
to the scheme presented in Fig. 1, Table 1, and Table 2,
and include a standardized interview to determine pa-
tient’s clinical condition and well-being, assessment of
various questionnaires, and laboratory assessment. Dur-
ing each visit, adverse events and concomitant medica-
tion are discussed. At each visit, the diary and residual
medications are collected.
Privacy of the patients is guaranteed; stored data and
materials are only identifiable to the person by a sequen-
tially assigned subject number. The handling of personal
data complies with the Dutch Personal Data Protection
Act (De Wet Bescherming Persoonsgegevens, WBP).
The SPIRIT checklist and figure for this study protocol
are shown in Additional files 1 and 2.
Adverse events
Adverse events will be recorded and monitored. The
principal investigator will be informed immediately in
case of any serious adverse event (SAE) occurring. Every
SAE will be reported to the Ethics Committee.
Statistical analysis
Sample size
A 1-point change on the PI-NRS compared to baseline
is considered as the minimum clinically important differ-
ence (MCID), according to the unified rule of ½ x SD
and recommendations given by the IMMPACT group
[38, 43]. In the placebo group, we assume a response
rate of approximately 25 % in the placebo-treated group,
based on a meta-analysis of the placebo effect in pain stud-
ies in which the effect varied from 7 to 37 %, and where
16 % of the patients had a pain reduction of 50 % [32]. In
the IVIg treated group, we assume a response rate of ap-
proximately 60 % based on the IMMPACTcriteria [38].
Fixing a one-sided alpha at 5 %, a sample size of 24 pa-
tients per treatment group would be required to show
efficacy with 80 % power and an effect size of 60 % be-
tween the two groups (chi-square test). Accounting for a
dropout rate of approximately 20 % (six patients), 30 sub-
jects per treatment group will be included in this study.
Type of analysis
The primary efficacy comparison is the comparison of
the proportion of responders in the per-protocol popula-
tion, where a responder is defined as ≥ 1-point improve-
ment in the mean weekly peak pain measured with the
PI-NRS (maximum pain) during the 12-week treatment
period after first study drug infusion compared to base-
line, using Kaplan-Meier curves (log rank test). The
following sensitivity analyses will be performed. The pri-
mary efficacy analysis will be repeated in the per-
protocol population using a more strict definition of a
responder: a “responder of ≥ 2 points” is defined as ≥ 2
points improvement in the PI-NRS at the last evaluation
after the first study drug infusion during the blinded 12-
week treatment period compared to baseline.
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In the intention-to-treat (ITT) population, the fol-
lowing additional sensitivity analyses will be per-
formed: any subject who drops out with at least the
week 6 PI-NRS assessment with their last mean
weakly peak pain on the PI-NRS will be carried for-
ward. A subject dropping out before the week 6 PI-
NRS assessment or any subject with no baseline PI-
NRS will be counted as a nonresponder independent
of the last PI-NRS. Furthermore, in the ITT popula-
tion, the following sensitivity analyses will be per-
formed. The analysis will be repeated using a more
strict definition of a responder: a “responder of ≥ 2
points” is defined as ≥ 2 points improvement in the
PI-NRS at the last evaluation following the first study
drug infusion during the blinded 12-week-treatment
period compared to baseline. Subjects with no base-
line or no postbaseline PI-NRS assessment will be
counted as a nonresponder in this analysis.
When values are missing, we will use multiple imput-
ation based on a regression method, using SPSS (IBM
Corp. Released 2015. IBM SPSS Statistics for Macintosh,
Version 22.0. Armonk, NY: IBM Corp) or Stata (Stata-
Corp. 2013. Stata Statistical Software: Release 13. College
Station, TX: StataCorp LP).
The differences between the per-protocol analyses and
the ITTanalyses will give a good impression of the bias that
might occur in the study. Comparing these two methods,
we can make a clear picture of the two populations and can
investigate the true effect of IVIg in the most reliable way.
The secondary efficacy variables will be tested for
treatment group differences by analyses of covariance
(ANCOVAs) with the baseline measurement as the
covariate and the difference of the last post-baseline
measurement in the treatment period relative to base-
line as an independent variable (treatment group as fixed
factor). If no postbaseline measurement is documented,
Table 1 Study flow chart (except laboratory assessments)


























Nerve Conduction Studies X
Skin biopsy and QST X
Laboratory Assessments
(see Table 2)
X X X X X X
PI-NRS X X X X
PGIC X X X
SFN-SIQ X X X X
NPS X X X X
SFN-RODS X X X X
Pain relief X X X
Sleep quality X X X X




Vital Signs2 X X X
Concomitant Medication X X X X X X X
Adverse Events X X X X X X X
1 Medications given over 2 consecutive days at baseline and over 1 day every 3 weeks thereafter. Treatment is allowed to be prolonged up to 4 or 2 days
respectively for reasons of tolerability
2 Vital signs (blood pressure and heart rate) to be taken right before infusion, 30 minutes after starting infusion, and immediately after infusion completed
3 Visit to be conducted after completion of entire baseline infusion (Day 2, 3, or 4 depending on duration of baseline infusion)
4 Visit to be conducted 3-6 days after completion of the baseline infusion, not 3-5 days after baseline/Day 1 infusion began
5 The follow-up period will be performed by standardized telephone call interviews
QST = quantitative sensory testing, PI-NRS = pain intensity numerical rating scale, PGIC = patients’ global impression of change, RT-SFN-SIQ = Rasch-transformed
small fiber neuropathy symptoms inventory questionnaire, NPS = neuropathic pain scale, SFN-RODS = small fiber neuropathy Rasch-built overall disability
outcome scale, SF-36 = short form 36 health survey
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the baseline measurement will be used as the last postba-
seline measurement. This analysis is an endpoint analysis
using the “last observation carried forward” (LOCF)
approach.
Discussion
In this study, the efficacy and safety of IVIg is evaluated in
patients with skin-biopsy-proven idiopathic SFN. This will
be the first randomized, placebo-controlled, double-blind,
clinical trial with IVIg versus placebo in patients with SFN.
In previous case studies with patients diagnosed with
SFN and an underlying autoimmune disease (such as
sarcoidosis, Sjögren’s syndrome, and celiac disease), IVIg
has shown to be effective on chronic pain [20, 21, 24]. In
addition, in chronic refractory pain in general, pain re-
duction after IVIg treatment has been described [23],
suggesting that immunological mechanisms may play a
role in the development or maintenance of pain, even if
no clear immunological disorders are present.
One of the limitations of the study is that the spe-
cific mechanism of action of IVIg is not known, mak-
ing it hard to predict which patients will benefit from the
treatment. A second limitation might be that the treat-
ment period of 3 months is too short to obtain effect.
Third, patients will be kept stable on their current pain
treatment, which could influence the results. However,
stopping current pain medication would be ethically
difficult.
In SFN, a better treatment is warranted because cur-
rently available (neuropathic) pain medication does not
relieve pain substantially and often has side effects [44].
For IVIg, both a complementary and diminishing action
on the immune system has been described [45]. In SFN,
an activated immune system probably causes inflamma-
tory responses to the small nerve fibers, which can be
diminished by IVIg.
Positive findings of IVIg treatment in SFN will result
in a new treatment option and may support an immuno-
logical role in this condition.
Trial status
Participant recruitment will start at the half of 2016.
Additional files
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 121 kb)
Additional file 2: Example template of recommended content for the
schedule of enrolment, interventions, and assessments*. (DOC 68 kb)
Abbreviations
Bw, body weight; DSIS, Daily Sleep Interference Scale; eCRF, electronic case
report file; GCP, good clinical practice; ICH, International Council for
Harmonisation; IENFD intraepidermal nerve fiber density; IMMPACT, Initiative
on Methods, Measurements and Pain Assessment in Clinical Trials; I-SFN,
idiopathic small fiber neuropathy; ITT, intention-to-treat; IVIg, intravenous
immunoglobulin; LOCF, last observation carried forward; MCID, minimum
clinically important difference; NPS, Neuropathic Pain Scale; PGIC, Patients’
Table 2 Study flow chart – laboratory assessments




Lab assessment - 10 days (Day







(Day 2 or 3 or
4)











Pregnancy Test (Serum β HCG) X
TSH1 / regular T4 X
Fasting blood glucose, vitamin B122 X
Serum Retain3 X X
Urinalysis X X
IgG4 X X4 X X X
Hematology/CBC (hematocrit,
hemoglobin, WBC, RBC, platelets)
X X X X X
Creatinine, Blood urea nitrogen X X X X X
AST/ALT, LDH, potassium, bilirubin, CK X X4 X X
Gamma-GT X X4 X X
1 TSH to be conducted at screening if results not available since SFN diagnosis. Regular T4 automatically run by LabCorp if TSH determined to be above the upper limits of normal
2 To be conducted at screening if results not available since SFN diagnosis
3 2 aliquots required at screening (one for viral retain and one for possible future antibody testing); 1 aliquot required at both Week 12 (for possible future antibody testing)
4 Samples to be obtained immediately after completion of entire baseline infusion. If the entire baseline infusion is completed in 2 days, then samples are to be
collected post-infusion on Day 2. If the entire baseline infusion is completed in 3 or 4 days, then samples are to be collected post-infusion on Day 3 or 4 respectively
5 The follow-up period will be performed by standardized telephone call interviews
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Global Impression of Change; PI-NRS, Pain Intensity Numerical Rating Scale;
RT-SFN-SIQ, Rasch-Transformed Small Fiber Neuropathy Symptoms Inventory
Questionnaire; SAE, serious adverse event; SF, 36 Short Form 36 Health
Survey; SFN, small fiber neuropathy; SFN-RODS, small fiber neuropathy
Rasch-built Overall Disability Outcome Scale; WBP, Wet Bescherming
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